Alimera Sciences
Latest round
- Series C
Last raised
- Aug 2009
Total raised
- $109M
Investors
- 5
About Alimera Sciences
Established in 2003 by Dan Myers and Dave Holland, and based in Georgia, US, Alimera Sciences, Inc. operates as a biopharmaceutical company that develops and commercializes prescription ophthalmic pharmaceuticals. The firm trades on NASDAQ under the ticker symbol ALIM. In April 2021, Alimera Sciences, Inc. Alimera Sciences is a global pharmaceutical company focused on retinal health. They develop innovative treatments for retinal diseases, aiming to improve vision and quality of life for patients. Their products address conditions affecting the retina and offer retinal disease therapies to better serve aging populations.
Who invested in Alimera Sciences
5 investors across 5 rounds
See all investors in Alimera Sciences
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Alimera Sciences
Who invested in Alimera Sciences?
Alimera Sciences has 5 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Alimera Sciences raised?
Alimera Sciences has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Alimera Sciences last raise money?
Alimera Sciences's most recent round on record is a Series C, in Aug 2009.
What does Alimera Sciences do?
Established in 2003 by Dan Myers and Dave Holland, and based in Georgia, US, Alimera Sciences, Inc.
Where is Alimera Sciences headquartered?
Alimera Sciences is headquartered in Alpharetta, US.
Which VCs invest in companies like Alimera Sciences?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Alimera Sciences's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like Alimera Sciences? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.